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Introduction
In 2001, the approval of imatinib, the first-in-class tyrosine
kinase inhibitor (TKI) targeting BCR-ABL, transformed the
prognosis of patients with chronic-phase (CP) chronic mye-
loid leukemia (CML) from a life-threatening condition to a
manageable and chronic disease.1 Yet, despite satisfactory
outcomes, 33% of patients did not achieved optimal response
because of treatment resistance or intolerance.1 The identi-
fication of the predominant resistancemechanism (i.e., point
mutations in the kinase domain of Bcr-Abl) led to the
development of second-generation BCR-ABL TKIs (dasatinib,
nilotinib, and bosutinib, respectively, approved in 2006,
2007, and 2012) active against most of the BCR-ABL mutated
forms.2,3 Second-generation TKIs demonstrated no or little
improvement of the overall survival compared with imati-
nib,4–6 but two of these (i.e., dasatinib and nilotinib) improve
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Abstract Imatinib, the first-in-class BCR-ABL tyrosine kinase inhibitor (TKI), had been a revolution for
the treatment of chronic myeloid leukemia (CML) and had greatly enhanced patient
survival. Second- (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKIs
have been developed to be effective against BCR-ABL mutations making imatinib less
effective. However, these treatments have been associated with arterial occlusive events.
This review gathers clinical data and experiments about the pathophysiology of these
arterial occlusive events with BCR-ABL TKIs. Imatinib is associated with very low rates of
thrombosis, suggesting a potentially protecting cardiovascular effect of this treatment in
patients with BCR-ABLCML. This protective effectmight bemediated by decreased platelet
secretion and activation, decreased leukocyte recruitment, and anti-inflammatory or
antifibrotic effects. Clinical data have guided mechanistic studies toward alteration of
platelet functions and atherosclerosis development, which might be secondary to
metabolism impairment. Dasatinib, nilotinib, and ponatinib affect endothelial cells and
might induce atherogenesis through increased vascular permeability. Nilotinib also impairs
platelet functions and induces hyperglycemia and dyslipidemia that might contribute to
atherosclerosis development. Description of the pathophysiology of arterial thrombotic
events is necessary to implement risk minimization strategies.
received
September 13, 2017
accepted after revision
November 27, 2017
DOI https://doi.org/
10.1055/s-0038-1624566.
ISSN 2512-9465.
© 2018 Georg Thieme Verlag KG
Stuttgart · New York
Review Article
THIEME
e68
surrogate outcomes and permit quicker and deeper achieve-
ment of molecular response, which is criteria to try treat-
ment cessation (i.e., MR4 or higher molecular response stable
for at least 2 years).7 Based on these results, dasatinib and
nilotinibwere approved in 2010 for frontlinemanagement of
CML, whereas bosutinib is used only after failure or intoler-
ance of first-line BCR-ABL TKIs. Unfortunately, these treat-
ments were ineffective against a common mutation (14% of
all mutations) in the gatekeeper residue of BCR-ABL (i.e., the
T315Ia mutation),8–10 requiring the development of a third-
generation TKI (ponatinib), efficient against this mutation.
Ponatinib is currently the only treatment active against the
T315I mutation and is therefore reserved for patients with
this mutation or for patients resistant to frontline
treatments.11
Since its approval, the first-generation TKI, imatinib, has
demonstrated reassuring safety profile, with low rate of
grade 3/4 adverse events and excellent tolerability.12,13
Conversely, new-generation BCR-ABL TKIs—nilotinib, dasa-
tinib, bosutinib, and ponatinib—are more recent and display
different safety profile. Dasatinib, nilotinib, and ponatinib
are largely associated with fluid retention and dasatinib
specifically induces high rate of pleural effusions.14–18 Nilo-
tinib induces metabolic disorders such as dyslipidemia and
hyperglycemia, whereas bosutinib safety profile is mainly
characterized by gastrointestinal events (i.e., diarrhea, nau-
sea, vomiting).19,20 Finally, ponatinib has been rapidly asso-
ciated with high rate of vascular occlusion.21
Recently, meta-analyses of randomized clinical trials
established that ponatinib is not the only new-generation
TKI that increases the cardiovascular risk.22,23 The four new-
generation BCR-ABL TKIs increase the risk of vascular occlu-
sive events compared with imatinib, especially arterial
occlusive diseases, and this is in accordance with clinical
trial data.22–25 However, this cardiovascular risk is contro-
versy for dasatinib because of the low incidence (1.1 per 100
patient-year) of cardiovascular events in clinical trials.26,27
Recently, a large retrospective analysis of CP-CML patients
treated with BCR-ABL TKIs at theMDAnderson Cancer Center
confirmed the increased risk of vascular occlusive events
with dasatinib.28 Another controversial point is the effect of
imatinib on the cardiovascular system. Indeed, imatinib is
associated with low risk of cardiovascular events and it was
therefore hypothesized that imatinib prevents their occur-
rence.29,30 Clinical data indicate that most patients develop-
ing arterial occlusive events with new-generation BCR-ABL
TKIs are high-risk patients, but cardiovascular events also
occurred in young and healthy patients. Additional informa-
tion on clinical safety of BCR-ABL TKIs is described in the
Supplementary Material (►Table S1). We assume that the
mechanism underlying arterial thrombosis with BCR-ABL
TKIs might be multiple. The predominance of arterial events
raised concerns about the impact of BCR-ABL TKIs on platelet
functions, atherosclerosis, and metabolism, and precluded
prothrombotic states to be responsible of these events.31
This review particularly focuses on the contribution of
glucose and lipid metabolism, atherosclerosis, and platelets
in the occurrence of cardiovascular events with new-gen-
eration TKIs. The last section discusses relevant off-targets
that might be implicated in the cardiovascular toxicity. The
discovery of the mechanism(s) by which arterial occlusive
events arose in CML patients would help in the management
of patients treated with BCR-ABL TKIs and implement risk
minimizationmeasures. Discovery of the pathophysiology of
these events in CML patients might also led to the develop-
ment of predictive biomarkers or to the development of new
therapies with no or reduced cardiovascular toxicity profile
while keeping an unaltered efficacy.
Impact on Platelet Functions
BCR-ABL TKIs are associated with both bleeding and throm-
botic complications. ►Table 1 describes experiments asses-
sing the impact of BCR-ABL TKIs on platelet production and
functions. Imatinib and dasatinib inducehemorrhagic events
in patients with CML. Interestingly, dasatinib-associated
hemorrhages occurred both in patients with and without
thrombocytopenia.32 In vitro and in vivo investigations
demonstrated that dasatinib affects both platelet functions
(i.e., platelet aggregation, secretion, and activation) and
platelet formation by impairment of megakaryocyte migra-
tion.33–36 Furthermore, dasatinib decreases thrombus for-
mation in vitro, in vivo, and ex vivo,34 and decreases the
number of procoagulant platelets (i.e., phosphatidylserine-
exposing platelets).35 Several dasatinib off-targets are impli-
cated in platelet signaling and functions including members
of the SFKs (e.g., Src, Lyn, Fyn, Lck, and Yes) (►Fig. 1).37,38
However, SFKs are also inhibited by bosutinib without dis-
turbance of platelet aggregation and adhesion. Dasatinib also
inhibits Syk, BTK, and members of the ephrin familyb (e.g.,
EphA2), all known to be involved in platelet functions.
Experimental assessments of platelet functions with ima-
tinib demonstrate less pronounced effects on platelets. Ima-
tinib inhibits platelet aggregation only at high doses,34 and
does not interfere with platelet aggregation in vivo.39 How-
ever, in vitro studies also indicate decreased platelet secre-
tion and activation by imatinib.34 The mechanism by which
imatinib inhibits platelet functions is unknown. Oppositely
to dasatinib, imatinib does not inhibit SFKs, ephrins, BTK, and
Syk. A hypothesis also suggests that imatinib induces bleed-
ing disorders because of BCR-ABL rearrangements in mega-
karyocytic cell lines, leading to clonal expansion of
dysfunctional megakaryocytes.40
Even if ponatinib induces very few bleeding disorders,
assessment of primary hemostasis in CML patients demon-
strated that ponatinib induces defect in platelet aggregation.
This impairment was found at all ponatinib dosage, in
patients with or without low platelet counts.41 These resultsa T315I: Substitution at position 315 in BCR-ABL from a threonine to
an isoleucine. This substitution alters the structure of the ATP-
binding pocket and eliminates a crucial hydrogen bond required for
binding of first- and second-generation TKIs.
b Ephrin family: Members of this family are involved in platelet
spreading, adhesion to fibrinogen and platelet secretion.
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were in accordance with in vitro studies which previously
demonstrated similar characteristics than dasatinib (i.e.,
decrease of platelet spreading, aggregation, P-selectin secre-
tion, and phosphatidylserine exposure).35,42 However, in
vitro assays tested ponatinib at 1 µM, a dose far higher
than the concentration observed in patients on treatment.43
Nilotinib and bosutinib are not associated with bleeding
disorders in CMLpatients. First in vitro studies demonstrated
little or no effect on platelet aggregation and activation with
these two TKIs.36,39,44 However, recent experiments
described prothrombotic phenotype of platelets induced
by nilotinib, with increase of PAR-1c–mediated platelet
secretion, adhesion, and activation, without disturbing pla-
telet aggregation.34 Additional studies demonstrated that
nilotinib increases secretion of adhesivemolecules as well as
thrombus formation and stability ex vivo.34
To summarize, dasatinib and imatinib induce hemorrha-
gic events through alteration of platelet functions, but the
molecular mechanism needs to be better determined. Pona-
tinib also impairs platelet functions. Therefore, no current
data involve platelets in the pathogenesis of arterial throm-
bosis occurring with dasatinib and ponatinib. Oppositely,
nilotinib might induce arterial thrombosis through altera-
tion of platelet secretion, adhesion, and activation.
Metabolic Dysregulation
Glucose Metabolism
BCR-ABL TKIs have contradictory effect on glucose metabo-
lism. Imatinib and dasatinib improve glucose metabolism
and type 2 diabetes management in CML patients (i.e.,
decrease of antidiabetic drug dosage and reversal of type 2
diabetes).14,45–49 This clinical profile is in accordancewith in
vivo studies in which imatinib is effective to prevent the
development of type 1 diabetes in prediabetic mice, without
impacting the adaptive immune system.50 Therefore, imati-
nib is currently tested in clinical trials for patients suffering
from type 1 diabetes mellitus (NCT01781975). The mechan-
ism(s) by which dasatinib and imatinib improve glucose
Fig. 1 Signaling pathways supporting platelet adhesion, activation, and aggregation. Tyrosine kinases are involved in several pathways and
contribute to platelet adhesion, aggregation, and activation. Important players in platelet signaling are members of the Src family kinases;
particularly Lyn, Fyn, and cSRC. These three tyrosine kinases are inhibited by dasatinib which might explain platelet dysfunction encountered
with this treatment. Additionally, dasatinib also inhibits BTK, Syk, EphA4, and EphB1—four tyrosine kinases involved in platelet activation and
aggregate stabilization. 5HT, 5-hydroxytryptamine; ADP, adenosine diphosphate; Btk, Bruton’s tyrosine kinase; Ca, calcium; Eph, ephrin; FcR, Fc
receptor; GP, glycoprotein; PAR, protease-activated receptor; PI3K, phosphoinositide 3-kinase; PLC, phospholipase C; TXA2, thromboxane A2;
vWF, Von Willebrand factor.
c PAR-1: protease-activated receptor 1. PAR receptors mediate
cellular effects of thrombin in platelets and endothelial cells.
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al.e72
metabolism remains unknown. Global hypotheses suggest
that imatinib increases peripheral insulin sensitivity, pro-
motes β-cell survival, or decreases hepatic glucose produc-
tion (►Fig. 2).51–54 This latter hypothesis (i.e., decreased
hepatic glucose production by imatinib) is not currently
the preferred theory, whereas it was demonstrated that
imatinib weakly affects hepatic glucose production.51 Sev-
eral targetsmight be involved in thismetabolic effect. PDGFR
has already been linked with type 1 diabetes reversal.50
Hägerkvist et al hypothesized that c-Abl inhibition by ima-
tinib promotes β-cell survival through activation of NF-κB
signaling and inhibition of proapoptotic pathways
(►Fig. 2).53,54 Inhibition of c-Abl in β-cells might also
increase insulin production and contribute to the glucose
regulation by imatinib.55 It was also speculated that imatinib
decreases insulin resistance in peripheral tissues due to c-
Abl-dependent JNK inactivation.d,51 Similar hypotheses
might be translated to dasatinib because of the similar off-
target inhibitory profile (i.e., dasatinib also inhibits c-Abl and
PDGFR). It was hypothesized that imatinib and dasatinib
impact glucose metabolism through reduced adipose
mass.51,56 However, clinical data do not demonstrate weight
loss in CML patients and do not favor this hypothesis. In both
imatinib- and dasatinib-treated patients, increased circulat-
ing adiponectine level correlates with decreased insulin
resistance.57,58 This correlation might be explained by the
translocation of the glucose transporter GLUT4f from the
cytoplasm to the cell membrane following adiponectin sig-
naling.59 Additionally, adiponectin has been related to
decreased hepatic glucose production which could be an
additional mechanism by which imatinib and dasatinib
improve glucose metabolism.60 It was speculated that the
raise of adiponectin level with imatinib and dasatinib is the
consequence of increased adipogenesis subsequent to
PDGFR inhibition.61
Fig. 2 Effects of BCR-ABL TKIs on glucose metabolism. Imatinib and dasatinib possess hypoglycemic effects, whereas nilotinib increases blood
glucose level and diabetes development. The figure describes glucose metabolism and boxes contain emitted hypotheses for effects of imatinib,
dasatinib, and nilotinib on glucose metabolism. Four major hypotheses have been emitted including impact on insulin production by β-cells, β-
cell survival, peripheral insulin sensitivity, and hepatic glucose production. ABL, Abelson; FAK, focal adhesion kinase; GLUT, glucose transporter;
IRS-1, insulin receptor substrate 1; JNK, c-Jun N-terminal kinases; MEKK1, MAPK/ERK kinase kinase 1; NF-κB, nuclear factor-kappa B; PDK1,
pyruvate dehydrogenase kinase 1; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species.
d JNK: c-Jun N-terminal kinases. JNK is responsive to stress stimuli
and mediates insulin resistance through inhibition of insulin
receptor substrate.
e Adiponectin is a protein regulating glucose metabolism. Adipo-
nectin increases peripheral insulin sensitivity by improving
glucose uptake.
f GLUT4: Glucose transporter type 4. GLUT4 is an insulin-regulated
glucose transporter expressed in peripheral tissues.
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Oppositely to imatinib and dasatinib, case reports and
clinical trials indicate that nilotinib increases blood glucose
level and promotes diabetes mellitus.62–65 Indeed, 20% of
nilotinib-treated patients developed diabetes after 3 years of
treatment,65whereas 29% of patients suffer from increase of
fasting glucose after 1 year of therapy.64 However, no varia-
tions of glycated hemoglobin were reported.64,65 Clinical
data indicate no direct effect of nilotinib on β-cells, but
suggest fasting insulin increase, fasting C-peptide decrease,
and an increase of HOMA-IR values (i.e., a model to assess
insulin resistance).64,66,67 Therefore, the preferred hypoth-
esis to explain the development of hyperglycemia is the
manifestation of insulin resistance. Weakened insulin secre-
tion occurred sometimes, but it is likely that this impairment
is the consequence of β-cell exhaustion.68 However, in vitro
experiments demonstrated inhibitory effect of nilotinib on
pancreatic cell growth.69 Breccia et al proposed an additional
hypothesis linking development of hyperglycemia and body
mass index. They suggested that the development of hyper-
glycemia might be the consequence of increase fat level
tissue resulting in decrease peripheral insulin sensitivity.70
However, dietetic measures to restrict glucose exogenous
uptake in patients who developed hyperglycemia were not
successful,63 and nilotinib does not induce changes in patient
body weight.71 Little is known regarding the mechanism by
which nilotinib induces insulin resistance. Racil et al sug-
gested that peripheral insulin resistance is mediated by c-Abl
inhibition which is involved in insulin receptor signaling
(►Fig. 2).67 This hypothesis is contrary to the hypothesis
described with dasatinib and imatinib in which c-Abl
enhances insulin sensitivity through c-Abl inhibition. These
two hypotheses describe different pathways involving c-Abl
but with opposite outcomes. To date, no hypothesis is pre-
ferred and additional studies are required to understand the
opposite effect on glucose metabolism between TKIs,
whereas both have been attributed to c-Abl inhibition.
Interestingly, Frasca et al described opposite role of c-Abl
in insulin signaling depending on the receptor involved, the
signaling pathway, and the cell context.72 Similar investiga-
tions should be performed in the context of c-Abl inhibition
by BCR-ABL TKIs. For bosutinib and ponatinib, little is known
regarding their impact on glucosemetabolism, but no drastic
changes in glucose profile has been reported during clinical
trials.
Fig. 3 Effects of BCR-ABL TKIs on lipid metabolism. Several hypotheses have been emitted to explain the imatinib-induced hypolipidemic effect.
Imatinib regulates expression of genes involved in lipid metabolism: Apobec1 that regulates ApoB expression through the introduction of a stop
codon into ApoBmRNA (ApoB is essential for VLDL production), and LDLR that is implicated in lipid clearance. Imatinib-induced PDGFR inhibition
influences LPL synthesis and dysregulates LRP. Dasatinib and nilotinib increase cholesterol plasma level through an unknown mechanism. Global
hypotheses can be emitted and include increased hepatic lipid synthesis (possibly related to hyperinsulinemia) and decreased lipid clearance
through LDLR functional defect or decreased LPL synthesis. ABC, ATP-binding cassette; C, cholesterol; CETP, cholesteryl ester transfer protein;
CM, chylomicron; FA, fatty acid; HMGCoA reductase, hydroxymethylglutaryl-CoA reductase; IDL, intermediate-density lipoprotein; LDL, low-
density lipoprotein; LDLR, low-density lipoprotein receptor; LPL, lipoprotein lipase; LRP, lipoprotein receptor-related protein; PDGFR, platelet-
derived growth factor receptor; VLDL, very low-density lipoprotein.
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Lipid Metabolism
Similarly with glucose metabolism, effects on lipid metabo-
lism are conflicting betweenTKIs. Oppositely to in vivo study
which demonstrated no impact of imatinib on total choles-
terol and triglycerides levels in diabetic mice,29 imatinib is
associated in CML patients with a rapid and progressive
decrease of cholesterol and triglycerides levels.66,73–75 First
hypothesis relates the inhibition of PDGFR by imatinib
(►Fig. 3). PDGFR is involved in the synthesis of the lipopro-
tein lipase (LPL) and in the regulation of the lipoprotein
receptor-related protein (LRP).73,74 However, all BCR-ABL
TKIs possess inhibitory activity against PDGFR but do not
share this positive impact on lipid profile. Recently, Ellis et al
described that imatinib impairs gene expression of proteins
involved in plasma lipid regulation. Indeed, in in vitro model
of CML cells, imatinib affects gene expression of four genes
implicated in lipid synthesis (HMG-CoA reductaseg gene and
apobec1h), lipid clearance (LDLR genei) and in exchange of
lipids from very low-density lipoprotein (VLDL) or low-
density lipoprotein (LDL) to high-density lipoprotein (HDL)
(CETPj gene). However, these studies were performed in a
model of CML cells and need to be confirmed in more
relevant models (e.g., primary cell lines, hepatocytes).76
Franceschino et al suggested that imatinib decreases diar-
rhea-related lipid absorption due to inhibition of c-kit in
interstitial Cajal cells (i.e., c-kit signaling is critical for the
survival and development of these cells).73 However,
this hypothesis is unlikely, few patients (3.3%) developed
grade 3/4 diarrhea, and patients treated with interferon-α
and cytarabine developed diarrhea at a same rate and do not
present lipid level reduction in the phase 3 clinical trial
(NCT00333840).
Oppositely, dasatinib and mostly nilotinib are associated
with an increase of cholesterol level.26,66,77Nilotinib induces
quick rise of total cholesterol, HDL, and LDL (i.e., within 3
months). Nilotinib-induced dyslipidemia are responsive to
statin and lipid level normalized after nilotinib discontinua-
tion.78 To date, the mechanism by which dasatinib and
nilotinib impact lipid metabolism is unknown. Future
researches should determine how these treatments induce
dyslipidemia. Global hypotheses could be formulated and
include an increase of lipid synthesis that might
be secondary to insulin resistance and hyperinsulinemia.
This hypothesis is particularly relevant with nilotinib and it
is also associated with hyperglycemia. Dasatinib and niloti-
nib might also decrease blood lipid clearance (e.g., distur-
bance of LDLR and LPL synthesis). The development of
dyslipidemia might contribute to the occurrence of arterial
occlusive events that occurred with nilotinib and dasatinib.
However, the relationship between impaired lipid metabo-
lism and cardiovascular occlusive events is unknown with
BCR-ABL TKIs, and there is no indication that correct man-
agement of lipidmetabolism can prevent arterial thrombosis
(e.g., stenosis occurred in a nilotinib-treated patient despite
the management of its hyperlipidemia through statin treat-
ment).79 On their side, bosutinib and ponatinib do not
disturb lipid metabolism.78,80
Effects on Atherosclerosis
Endothelial Dysfunction
►Fig. S1 in the Supplementary Material details the role of
endothelial cells (ECs) in atherosclerosis. Several in vitro and
in vivo experiments assess the impact of imatinib on EC
viability and functions (►Table 2). These studies demon-
strate that imatinib does not affect EC viability nor induce
apoptosis but increases EC proliferation.39,81–84 Only one
study reports a proapoptotic effect of imatinib on ECs, but
their experiments were performed on a cell line (i.e., EA.
hy926 cells),85 a model less reliable than primary cultures
(e.g., HUVEC,k HCAECl). In vitro studies also assessed the
effect of imatinib on EC functions. In these studies, imatinib
does not influence adhesion molecule expressions (i.e.,
ICAM-1m and VCAM-1n), EC migration, reactive oxygen
species (ROS) production, nor angiogenesis.81,82,85–87 Let-
siou et al suggested that imatinib decreases EC inflammation
by decreasing the secretion of proinflammatorymediators.86
The impact of imatinib on endothelial permeability is not
clear. Indeed, in vitro studies demonstrate that imatinib
increases endothelial permeability by decreasing the level
of plasma membrane VE-cadherin,o,85,86 whereas in vivo
experiments indicate decreased vascular leak following ima-
tinib treatment in a murine model of acute lung injury.88
Additionally, imatinib has been tested in patients suffering
from acute lung injury, a disease characterized by vascular
leakage, and demonstrate promising clinical efficacy. There-
fore, imatinib might positively affect atherogenesis by
decreasing endothelial inflammation and reducing vascular
leakage.
Nilotinib and ponatinib reduce EC proliferation andmight
impaired endothelial regeneration.39,82,89,90 Additionally,
ponatinib induces EC apoptosis, although it is well recog-
nized that high glucose concentration induces EC death,91
suggesting that nilotinib might, by this intermediary, affect
EC viability. Moreover, clinical data indicate that dasatinib
induces pulmonary arterial hypertension, whereas imatinib
is possibly beneficial in this disease.92,93 This pathology is
initiated by dysfunction or injury of pulmonary ECs.87
g HMGCoA reductase: 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase. HMGCoA reductase catalysis is the conversion of
HMG-CoA to mevalonic acid, an essential step in cholesterol
synthesis.
h Apobec1: Apolipoprotein B mRNA editing enzyme catalytic subunit
1. Apobec1 introduces a stop codon into ApoB mRNA.
i LDLR: Low-density lipoprotein receptor. This cell surface receptor
mediates LDL endocytosis.
j CETP: Cholesteryl ester transfer protein.
k HUVEC: Human umbilical vein endothelial cells.
l HCAEC: Human coronary artery endothelial cells.
m ICAM-1: Intercellular adhesion molecule 1. ICAM-1 stabilizes
leukocyte-endothelial cell adhesion and facilitates leukocyte
transmigration.
n VCAM-1: Vascular cell adhesion molecule 1. VCAM-1 mediates
rolling-type and firm adhesion of leukocyte.
o VE-cadherin: Vascular endothelial cadherin. VE-cadherin is a cell–
cell adhesion molecules and implies in endothelial junctions.
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Therefore, in vivo and in vitro studies investigated effect of
imatinib and dasatinib on pulmonary ECs and demonstrate
that dasatinib induces apoptosis on pulmonary ECsmediated
by increased mitochondrial ROS production.87 Future
researches should assess if this effect is also found in arterial
ECs and ROS production should also be tested with other
new-generation BCR-ABL TKIs.
In addition to their effect on EC viability, nilotinib and
ponatinib also influence EC functions, inhibit their migra-
tion, and decrease angiogenesis.39,82 It was suggested that
the antiangiogenic effect of ponatinib is the consequence of
VEGFRp inhibition, but this hypothesis cannot explain the
antiangiogenic effect of nilotinib (i.e., nilotinib does not
inhibit VEGFR).82 Nilotinib also increases adhesion molecule
expressions (i.e., ICAM-1, VCAM-1, and E-selectin) in vitro,39
suggesting that nilotinib might increase leukocyte recruit-
ment. However, further experiments are needed to validate
this hypothesis (e.g., assessment of endothelium permeabil-
ity and transendothelial migration). Dasatinib also induces
endothelium leakage in vitro, and the RhoA-ROCKq pathway
is involved in this phenomenon.94 It was demonstrated that
RhoA activation induces the phosphorylation of myosin light
chain that increases the actomyosin contractibility and dis-
rupt endothelial barrier.94 Therefore, increased endothelium
permeability is a potential mechanism by which dasatinib
and nilotinib promote atherosclerosis development and
arterial thrombosis. Likewise, it is plausible that ponatinib
affects endothelium integrity because of its inhibitory activ-
ity against VEGFR, which is recognized as a permeability-
inducing agent. Additional hypotheses suggest that inhibi-
tion of Abl kinase (i.e., Argr and c-Abl) and PDGFR might also
be implicated in vascular leakage.85 Finally, Guignabert et al
demonstrated that both in rats and in CML patients taking
dasatinib, there is an increase of soluble adhesionmolecules,
which arewell-knownmarkers of endothelial dysfunction.87
Inflammation
►Fig. S2 in the Supplementary Material describes the role of
immune cells and inflammation process during
atherosclerosis. ►Table 3 summarizes in vitro studies that
investigate impacts of BCR-ABL TKIs on survival, prolifera-
tion, andmajor functions ofmonocytes,macrophages, and T-
lymphocytes. Globally, in vitro studies demonstrate that
imatinib inhibits the development and maturation of mono-
cytes and alters monocyte functions.95,96 Imatinib decreases
production of proinflammatory cytokines (i.e., TNF-αs and
IL-6t) and diminishes the potential of monocytes to phago-
cytose.97,98 These impacts on monocyte functions are pos-
sibly related to c-fmsu inhibition.99 Imatinib also inhibits
macrophage functions in vitro. Imatinib decreases lipid
uptake without impacting the lipid efflux and decreases
activity and secretion of two matrix metalloproteinases
(MMPs; i.e., MMP-2 and MMP-9v) on a posttranscriptional
level.100 Additionally, imatinib inhibits T-lymphocyte acti-
vation and proliferation and decreases proinflammatory
cytokines secretion (i.e., IFN-γw).101 The inhibition of mono-
cyte, macrophage, and T-cell functions by imatinib might
prevent the development of atherosclerosis or reduce the
risk of atherosclerotic plaque rupture.
Effects of new-generation TKIs on inflammatory cells
were less studied, but first experiments indicate similarities
with imatinib about its impact on monocytes and macro-
phages. Both dasatinib and nilotinib have similar inhibitory
profile on macrophage-colony formation that has been
linked to CSFR inhibition.96,102 Dasatinib also possesses
anti-inflammatory functions by attenuating proinflamma-
tory cytokines production (i.e., TNF-α, IL-6, and IL-12x) by
macrophages and increasing production of anti-inflamma-
tory mediator (i.e., IL-10y).103 These effects are thought to be
mediated by SIKz inhibition, a subfamily of three serine/
threonine kinases that regulate macrophage polariza-
tion.103,104 Finally, dasatinib is associated with decreased
T-cell functions and particularly it decreases the production
of proinflammatory cytokines (e.g., TNF-α, IFN-γ) and che-
motactic mediators.105 Nilotinib and bosutinib also possess
anti-inflammatory activity and decrease cytokine produc-
tion and T-cell activation.103,106 Inhibition of Lck,ai a tyrosine
kinase implicated inT-cell receptor signaling, is implicated in
the impairment of T-cell functions by dasatinib and niloti-
nib.107,108 It has been hypothesized that nilotinib decreases
mast cell activity through c-kit inhibition,62,109 which might
result in a decrease of the vascular repair system.39,62
Clinical profile of nilotinib in patients with CML consolidates
this hypothesis and demonstrates a decreased of mast cell
level.39 However, similar decreased of mast cell is also
reported with imatinib without high rate of arterial
thrombosis.110
Globally, BCR-ABL TKIs possess reassuring profile on
inflammatory cells. However, impact of new-generation
TKIs on several functions of macrophages have not been
assessed (e.g., MMP secretion and activity, lipid uptake, and
p VEGFR: Vascular endothelial growth factor. This protein plays
major roles in vasculogenesis and angiogenesis.
q RhoA-ROCK: Ras homolog gene family, member A—Rho-associated
protein kinase. Rho-kinase regulates cytoskeletal reorganization,
cell migration, cell proliferation, and survival.
r Arg: Abelson-related gene (also known as ABL2). Arg possesses
cytoskeletal-remodeling functions.
s TNF-α: Tumor necrosis factor alpha. This cytokine is mainly
involved in systemic inflammation and regulates immune cells.
t IL-6: Interleukin 6. IL-6 is a proinflammatory cytokine secreted by
T-cells and macrophages to stimulate immune response.
u CSFR: Colony-stimulating factor receptor. CSFR drives growth and
development of monocytes.
v MMP-2 and MMP-9 are two proteases capable of degrading
extracellular matrix components. These two MMPs are the main
proteases involved in atherogenesis.
w IFN-γ: Interferon gamma. IFN-γ is involved in innate and adaptive
immunity and activates macrophages.
x IL-12: Interleukin 12. IL-12 is involved in T-cell differentiation and
functions.
y IL-10: Interleukin 10. IL-10 exerts immunoregulation and regulates
inflammation.
z SIK: Salt-inducible kinase. SIKs regulate production of anti- and
proinflammatory cytokines.
ai Lck: Lymphocyte-specific protein tyrosine kinase. Lck is mostly
involved in T-cell maturation.
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foam cell formation), whereas effect of ponatinib on inflam-
matory cells is unknown. The assessment of lipid uptake and
foam cell formation is particularly relevant with new-gen-
eration TKIs because there are numerous interactions
between TKIs and ABC transporters.aii,111,112
Fibrous Cap Thickness
►Fig. S3 in the Supplementary Material describes the
mechanism by which atherosclerotic plaque ruptures and
induces arterial thrombosis. ►Table 4 summarizes in vitro
and in vivo experiments performed on VSMCs and fibro-
blasts. Imatinib decreases VSMC proliferation and growth
but results are conflicting about its impact on apoptosis.
Some studies demonstrate no impact on SMC apoptosis,
whereas others indicate increased SMC death.83,113–116 Ima-
tinib also affects VSMC functions and decreases their migra-
tion and LDL binding, inducing decreased LDL retention by
the sub-endothelium.113,117 Imatinib also exerts negative
effect on the synthesis of major ECM components (type I
collagen and fibronectin A) by fibroblasts, correlating to
decreased ECM accumulation in vivo.118 The impact of
imatinib on SMCs is thought to be mediated by PDGFR
inhibition,114 which is involved in several VSMC functions
including VSMC survival and plasticity.113 Subsequent to the
hypothesis that imatinib inhibits PDGFR signaling, prevents
abundant SMC and fibroblast proliferation, and inhibits
abundant ECM accumulation, imatinib has been tested for
themanagement of several fibrotic diseases (e.g., dermal and
liver pulmonary fibrosis, systemic sclerosis).30,118,119 Imati-
nib successfully acts on pulmonary fibrosis and pulmonary
arterial hypertension (i.e., a disease involving vascular remo-
deling mediated by pulmonary SMC proliferation),93,114 and
has beneficial activity in sclerotic chronic graft-versus-host
disease.120 Finally, imatinib was tested in vivo for the pre-
vention of cardiovascular diseases and demonstrates efficacy
for the treatment of myocardial fibrosis by reducing ECM
component synthesis (i.e., procollagen I and III).30 In a rat
model, imatinib successfully inhibits stenosis after balloon
injury and presents interest in intimal hyperplasia and
stenosis after bypass grafts.115,116,121–123 Imatinib also suc-
cessfully prevents arterial thrombosis following microvas-
cular surgery in rabbits.124 Imatinibwas also encompassed in
a stent but do not demonstrate efficacy in restenosis
prevention.84
Impact of new-generation TKIs on fibrosis was less stu-
died but demonstrate similar inhibitory effect on VSMCs and
fibroblasts. Indeed, dasatinib inhibits PDGFR more potently
than imatinib,113 and the hypothesis that dasatinib prevents
restenosis similarly with imatinib was emitted. Therefore, a
patent has been filed claiming the use of dasatinib for the
prevention of stenosis and restenosis.125 Compared with
imatinib, dasatinib has additional off-targets and is able to
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aii ABC transporter: ATP-binding cassette transporters. ABCG1 and
ABCA1 are implicated in macrophage reverse cholesterol transport.
Their deficiency leads to foam cell formation and atherosclerosis
development.
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al.e80
Ta
b
le
4
In
vi
tr
o
an
d
in
vi
vo
st
ud
ie
s
on
ef
fe
ct
s
of
BC
R
-A
BL
TK
Is
on
pr
ol
ife
ra
ti
on
,
su
rv
iv
al
,a
nd
m
aj
or
fu
nc
ti
on
s
of
sm
oo
th
m
us
cl
e
ce
lls
an
d
fi
br
o
bl
as
ts
En
d
p
oi
nt
s
M
et
ho
d
s
M
od
el
s
TK
Is
Fi
n
d
in
g
s
Re
f.
Pr
ol
ife
ra
ti
on
/
su
rv
iv
al
Re
sa
zu
ri
n
as
sa
y;
im
m
un
o
fl
uo
re
sc
en
ce
;
3
H
-t
hy
m
id
in
e
in
co
rp
or
at
io
n;
Br
d
U
in
co
rp
or
at
io
n;
M
TT
as
sa
y
H
V
SM
C
;B
A
oS
M
C
;P
A
SM
C
;A
SM
C
;
V
SM
C
;H
A
oS
M
C
;
H
C
A
SM
C
;
Ra
bb
it
Im
at
in
ib
SM
C
pr
ol
ife
ra
ti
on
83
,8
4,
1
14
–1
16
,1
23
,1
55
C
as
p
as
e
as
sa
y;
PA
R
P
(W
es
te
rn
bl
ot
);
JC
-
1
dy
e;
A
nn
ex
in
V
st
ai
ni
ng
BA
o
SM
C
;D
er
m
al
fi
br
ob
la
st
;
PA
SM
C
Im
at
in
ib
¼
SM
C
/fi
br
ob
la
st
ap
op
to
si
s
83
,1
18
,1
55
TU
N
EL
;c
as
p
as
e
as
sa
y
PA
SM
C
;
H
A
oS
M
C
;
Ra
bb
it
Im
at
in
ib
SM
C
ap
op
to
si
s
(P
D
G
F-
st
im
ul
at
ed
)
11
4,
11
6,
12
3
Tr
yp
an
bl
ue
ex
cl
us
io
n
H
C
A
SM
C
;A
10
ce
ll
lin
e
Im
at
in
ib
¼
SM
C
vi
ab
ili
ty
84
C
el
lc
ou
nt
in
g
;
Pr
op
id
iu
m
io
di
d
e
st
ai
ni
ng
A
10
ce
ll
lin
e,
H
A
o
SM
C
D
as
at
in
ib
SM
C
pr
ol
ife
ra
ti
on
11
3,
12
5
M
ig
ra
ti
on
Tr
an
sw
el
lc
el
lm
ig
ra
ti
on
as
sa
y
H
A
oS
M
C
;
PA
SM
C
;
H
C
A
SM
C
;
A
10
ce
ll
Im
at
in
ib
SM
C
m
ig
ra
ti
on
84
,1
16
,1
55
Tr
an
sw
el
lc
el
lm
ig
ra
ti
on
as
sa
y
H
A
oS
M
C
;
A
10
ce
ll
D
as
at
in
ib
SM
C
m
ig
ra
ti
on
11
3,
12
5
Se
cr
et
io
n/
sy
nt
he
si
s
R
ad
io
la
be
li
nc
or
po
ra
ti
on
H
um
an
V
SM
C
Im
at
in
ib
pr
ot
eo
gl
yc
an
sy
nt
he
si
s
11
7
RT
-P
C
R;
W
es
te
rn
bl
ot
;
Si
rc
ol
co
lla
ge
n
as
sa
y
D
er
m
al
fi
br
ob
la
st
Im
at
in
ib
CO
L1
A
1,
CO
L1
A
2,
fib
ro
ne
ct
in
1
sy
nt
he
si
s
co
lla
ge
n
sy
nt
he
si
s
11
8
RT
-P
C
R
D
er
m
al
fi
br
ob
la
st
Im
at
in
ib
¼
M
M
P-
1,
M
M
P-
2,
TI
M
P-
1,
TI
M
P-
2,
TI
M
P-
3
an
d
TI
M
P-
4
11
8
qR
T-
PC
R
H
um
an
fi
br
o
bl
as
t
N
ilo
ti
ni
b
D
ec
re
as
es
C
O
L1
A
1
an
d
C
O
L1
A
2
sy
nt
he
si
s
12
7
Fi
br
o
si
s
Si
ri
us
re
d
st
ai
ni
ng
Ra
t
Im
at
in
ib
m
yo
ca
rd
ia
lf
ib
ro
si
s,
liv
er
fib
ro
si
s
30
,1
19
In
ti
m
a/
m
ed
ia
ra
ti
o
Ra
t
(B
al
lo
o
n
in
ju
ry
m
od
el
)
Im
at
in
ib
st
en
os
is
12
1,
12
2
In
ti
m
a/
m
ed
ia
ra
ti
o
Ra
bb
it
Im
at
in
ib
in
ti
m
al
th
ic
kn
es
s
12
4
H
yd
ro
xy
pr
ol
in
e,
co
lla
ge
n
co
nt
en
t
Ra
t
liv
er
Im
at
in
ib
hy
dr
ox
yp
ro
lin
e
an
d
co
lla
ge
n
co
nt
en
t
12
8
H
yd
ro
xy
pr
ol
in
e,
co
lla
ge
n
co
nt
en
t
Ra
t
liv
er
N
ilo
ti
ni
b
hy
dr
ox
yp
ro
lin
e
an
d
co
lla
ge
n
co
nt
en
t
12
8
Si
ri
us
re
d
st
ai
ni
ng
Ra
t
liv
er
N
ilo
ti
ni
b
liv
er
fib
ro
si
s
12
8
A
b
br
ev
ia
ti
on
s:
A
SM
C
,a
rt
er
ia
ls
m
oo
th
m
us
cl
e
ce
ll;
BA
oS
M
C
,b
ov
in
e
ao
rt
ic
sm
oo
th
m
us
cl
e
ce
ll;
Br
dU
,b
ro
m
od
eo
xy
ur
id
in
e;
C
O
L,
co
lla
ge
n;
H
aO
SM
C
,h
um
an
ao
rt
ic
sm
oo
th
m
us
cl
e
ce
ll;
H
C
A
SM
C
,h
um
an
co
ro
na
ry
ar
te
ry
sm
oo
th
m
us
cl
e
ce
ll;
H
V
SM
C
,
hu
m
an
va
sc
u
la
r
sm
oo
th
m
us
cl
e
ce
ll;
M
M
P,
m
at
ri
x
m
et
al
lo
p
ro
te
in
as
e;
PA
R
P,
po
ly
(A
D
P-
ri
bo
se
)
po
ly
m
er
as
e;
PA
SM
C
,
pu
lm
on
ar
y
sm
oo
th
m
us
cl
e
ce
ll;
PD
G
F,
pl
at
el
et
-d
er
iv
ed
gr
ow
th
fa
ct
or
;q
RT
-P
C
R
,q
ua
nt
it
at
iv
e
re
ve
rs
e
tr
an
sc
ri
pt
io
n
po
ly
m
er
as
e
ch
ai
n
re
ac
ti
on
;S
M
C
,s
m
o
ot
h
m
us
cl
e
ce
ll;
TI
M
P,
ti
ss
ue
in
hi
bi
to
r
of
m
et
al
lo
pr
ot
ei
na
se
;T
U
N
EL
,t
er
m
in
al
de
ox
yn
uc
le
ot
id
yl
tr
an
sf
er
as
e
dU
TP
ni
ck
en
d
la
be
lin
g
;
V
SM
C
,
va
sc
ul
ar
sm
oo
th
m
us
cl
e
ce
ll.
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al. e81
inhibit Src,aiii a kinase involved in dermal fibrosis in addition
to PDGFR.126 Therefore, dasatinibwas tested in patients with
scleroderma-like chronic graft-versus-host disease, a disease
resulting from inflammation and progressive fibrosis of the
dermis and subcutaneous tissues, and first results are
encouraging.126 Nilotinib also appears to be clinically effi-
cient in scleroderma-like graft-versus-host disease by redu-
cing collagen expression.127 Finally, nilotinib was tested in
vivo for the treatment of liver fibrosis and demonstrates
decreased fibrotic markers and inflammatory cytokines (IL-
1α, IL-1β, IFN-γ, IL-6).128 However, only low-dose nilotinib
was found to be efficient against fibrosis and normalized
collagen content.128 This lack of antifibrotic effect at higher
doses might be explained by inhibition of additional off-
targets by nilotinib that affect the benefit of low-dose
nilotinib against fibrosis. Arterial thrombosis occurring
with dasatinib and nilotinib are probably not the conse-
quence of VSMC impairment, but investigations should be
performed on VSMCs rather than on fibroblasts. Additional
investigations are warranted to complete impact of BCR-ABL
TKIs on VSMC functions (e.g., VSMC apoptosis, proliferation,
and migration) and confirm their safety toward VSMCs.
Off-targets
BCR-ABL TKIs bind the highly conserved ATP binding site and
arethereforenot veryspecific toBCR-ABL andpossessmultiple
cellular targets (kinases and nonkinase proteins).129,130 This
allowed the possibility to exploit them in other indications
(e.g., PDGFR inhibitionby imatinib isused inBCR-ABL-negative
chronic myeloid disorders),131 but this may also induce toxi-
cities and side effects.129 The development of arterial throm-
botic events with new-generation BCR-ABL TKIs is likely to be
related to inhibition of off-targets, as described throughout
this review. ►Fig. 4 describes inhibitory profiles of imatinib,
dasatinib, nilotinib, bosutinib, and ponatinib. Globally, imati-
nib is the most selective BCR-ABL TKIs, whereas dasatinib and
ponatinib inhibit numerous off-targets.
However, inhibitory profiles are difficult to determine and
several researches published discrepancies. For conflicting
results, a conservative approach has been applied in ►Fig. 4,
but supplementary information (►Table S2) describes the tyr-
osine kinase selectivity profile of the five BCR-ABL TKIs and
indicates divergences between studies.43,130,132–134 These dis-
crepancies can be explained by the difference in drug concentra-
tionandmethodologies.Todate, severalmethodshavebeenused
todetermine inhibitoryprofile of BCR-ABLTKIs including invitro
kinase assay,133–135 kinase expression in bacteriophages,136 and
Fig. 4 Specificity of imatinib, dasatinib, nilotinib, and ponatinib toward tyrosine kinases. Green, yellow, red, and blue circles contain tyrosine
kinase inhibited by dasatinib, nilotinib, bosutinib, and ponatinib, respectively. Tyrosine kinases in white represent imatinib off-targets. This figure
summarizes results from 13 experiments.39,43,130,132–137,156–159 In case of conflictual results between studies, a conservative approach has
been applied. Additional information is provided in the Supplementary Material.
aiiiSrc is involved in angiogenesis and cell survival and proliferation.
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affinity purification methods combined with mass spectropho-
tometry.130,132 However, all these methods suffer from caveats,
including the incompatibility to perform live-cell studies. A cell-
permeablekinaseprobewasdevelopedtofigureoutthisproblem,
butthisassayisstill limitedbythenumberofoff-targettested(i.e.,
it requires to predefine tested off-targets) and therefore, the
missing of targets is possible.137 For this reason, the inhibitory
activityofeachTKIhasnotbeen tested towardall tyrosinekinase
and►Fig. 4 includes onlyoff-targets forwhich at least oneof the
fiveBCR-ABLTKIhasbeentested.Thus, inhibitoryprofilesneedto
be carefully considered and it has to keep in mind that BCR-ABL
TKI metabolites may possess activity against supplemental off-
targets.
As described over this review, PDGF signaling has count-
less effects on several cells and tissues and is involved in
several proatherogenic mechanisms (e.g., adipogenesis, vas-
cular leakage, VSMC viability, and functions) and vascular
homeostasis, which led to the suggestion of its implication in
the potential beneficial cardiovascular effect of imati-
nib.116,123,138 However, dasatinib, nilotinib, and ponatinib
also inhibit PDGFR but increase the risk of arterial occlusive
events. This difference of clinical outcome might be
explained by the concentration of BCR-ABL TKIs necessary
to obtain a same degree of PDGFR inhibition.43 Indeed, Rivera
et al reported that when adjusted to the maximum serum
concentration, imatinib inhibits more profoundly PDGFR
than dasatinib, nilotinib, and ponatinib.43 Therefore, at
effective concentration, it is probable that the degree of
PDGFR inhibition is too low with dasatinib, nilotinib, and
ponatinib to obtain the beneficial effect of PDGFR inhibition
on atherosclerosis. Another possible hypothesis concerns the
less conclusive specificity of new-generation TKIs which
leads to inhibition of additional off-targets that might coun-
terbalance the positive effect of PDGFR inhibition.
Other tyrosine kinases have been incriminated in the occur-
renceof arterial thrombosiswithnew-generationTKIs. DDR-1aiv
possesses functions in vascular homeostasis, atherogenesis,
and is expressed in pancreatic islet cells. However, and
similarly with PDGFR, it is inhibited by all BCR-ABL
TKIs.26,62 Other hypotheses include impairment of VEGF
signaling by ponatinib43,90 or the inhibition of several ephrin
receptors by new-generation TKIs but not by imatinib which
might inhibit monocyte recruitment.139 Finally, it has
been suggested that the inhibition of c-Abl itself is implica-
ted in the increase of the cardiovascular risk. Indeed, ima-
tinib possesses lower inhibitory effect on c-Abl than
new-generation TKIs, which might further explain the
difference in cardiovascular safety.43 Additionally, c-Abl
modulates Tie-2,av a tyrosine kinase that possesses impor-
tant effect on endothelial cell function, angiogenesis, and
inflammation.140,141
Perspectives and Conclusions
This review summarizes the data underlying the potential
preventive effect of imatinib on the occurrence of arterial
thrombosis. Globally, in vitro and in vivo experiments
demonstrate that imatinib possesses antiplatelet activity,
hypolipidemic and hypoglycemic effects, and inhibits
inflammation and atherosclerosis development in several
cell types (i.e., decreases of inflammatory cell and VSMC
functions and increased vascular permeability). These ben-
efits were largely attributed to PDGFR inhibition. It is cur-
rently unknown why new-generation TKIs that also inhibit
PDGFR present opposite cardiovascular safety profile and
this point needs to be elucidated.
New-generation BCR-ABL TKIs increase the risk of arterial
thromboembolismwith different clinical features (e.g., time-
to-event and absolute rate) and are associated with different
safety profiles, suggesting different pathways to explain the
pathophysiology. The safety profile of nilotinib is mostly
characterized by impaired glucose and lipid metabolism.
However, both themolecularmechanism of these alterations
and their impact on the occurrence of arterial thrombosis are
unknown. Both dasatinib and ponatinib exhibit antiplatelet
effect, whereas it was recently suggested that nilotinib
potentially induces prothrombotic phenotype of platelets.
Based on the clinical characteristics and case reports, ather-
osclerosis appears the most plausible mechanisms by which
new-generationTKIs induce arterial thrombosis. However, in
vitro and in vivo studies of viability and functions of SMCs
and inflammatory cells demonstrate reassuring impact of
dasatinib and nilotinib, even if additional studies are
required to complete this evaluation. However, first experi-
ments indicate that dasatinib, nilotinib, and ponatinib influ-
ence EC survival and/or endothelium integrity, suggesting a
reasonable hypothesis by which new-generation TKIs induce
atherosclerosis development and, subsequently, arterial
thrombosis. Additional studies on the shedding of functional
extracellular vesicles by endothelial cells might be interest-
ing regarding their important role in coronary artery dis-
eases.142 Finally, the impact of new-generation TKIs on
human blood coagulation and fibrinolysis has never been
studied and should be addressed.
To conclude, new-generation TKIs increase the risk of
arterial thrombosis in patients with CML, whereas imatinib,
the first-generation TKI, might prevent the development of
cardiovascular events. To date, the cellular events and signal-
ing pathways by which these events occurred are unknown
and researches are extremely limited focusing mainly on
imatinib and nilotinib. Researches need to be extended to all
new-generation BCR-ABL TKIs (i.e., dasatinib, bosutinib, and
ponatinib). The understanding of the mechanisms by which
new-generation BCR-ABL TKIs induce or promote arterial
occlusive events will improve the clinical uses of these
therapies. To date, only general risk minimization measures
have been proposed (e.g., management of dyslipidemia,
aivDDR-1: Discoidin domain receptor tyrosine kinase 1. DDR1 is
involved in the regulation of cell growth, differentiation, and
metabolism.
av Tie-2: Tunica interna endothelial cell kinase. Tie-2 regulates
angiogenesis, endothelial cell survival, proliferation, migration,
adhesion and cell spreading, cytoskeleton reorganization, and
vascular quiescence. Tie-2 also possesses anti-inflammatory func-
tions by preventing the leakage of proinflammatory mediators and
leukocytes.
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diabetes, arterial hypertension following standard of
care).14,22,23,143–146 The understanding of the pathophysiol-
ogy is required to implement the most appropriate risk
minimization strategies for thrombotic events and to select
patients to whom the prescription of these drugs should be
avoided when applicable. Finally, the understanding of the
pathophysiology will help in the design of new BCR-ABL
inhibitors sparing the toxic targets.
Review Criteria
Relevant articles published from the database inception to
July 11, 2017, were identified from an electronic database
(PubMed) using the keywords “vascular,” “thrombosis,”
“atherosclerosis,” “arteriosclerosis,” “venous,” “arterial,”
“hemostasis,” “metabolic,” “metabolism,” “glycemia,” “gly-
caemia,” “cholesterol,” “triglycerides,” and “platelet” com-
bined with the five approved BCR-ABL TKIs. The search
strategy is presented in supplementary files. Articles pub-
lished in languages other than English were excluded from
the analysis. Primary criteriawere pathophysiological expla-
nation of arterial thrombotic events. Abstracts and full-text
articles were reviewedwith a focus on atherogenesis, plaque
rupture, platelet functions, and their link with the develop-
ment of arterial thrombosis with BCR-ABL TKIs. The refer-
ence section of identified articles was also examined.
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